Topics

PubMed Journals Articles About "Ofatumumab 1000 Vial Leukaemia Lymphocytic Chronic" RSS

06:31 EST 22nd January 2020 | BioPortfolio

Ofatumumab 1000 Vial Leukaemia Lymphocytic Chronic PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Ofatumumab 1000 Vial Leukaemia Lymphocytic Chronic articles that have been published worldwide.

More Information about "Ofatumumab 1000 Vial Leukaemia Lymphocytic Chronic" on BioPortfolio

We have published hundreds of Ofatumumab 1000 Vial Leukaemia Lymphocytic Chronic news stories on BioPortfolio along with dozens of Ofatumumab 1000 Vial Leukaemia Lymphocytic Chronic Clinical Trials and PubMed Articles about Ofatumumab 1000 Vial Leukaemia Lymphocytic Chronic for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Ofatumumab 1000 Vial Leukaemia Lymphocytic Chronic Companies in our database. You can also find out about relevant Ofatumumab 1000 Vial Leukaemia Lymphocytic Chronic Drugs and Medications on this site too.

Showing "ofatumumab 1000 vial Leukaemia Lymphocytic Chronic" PubMed Articles 1–25 of 8,900+

The landscape of genetic mutations in patients with chronic lymphocytic leukaemia and complex karyotype.


Somatic mutations in myelodysplastic syndrome with ring sideroblasts and chronic lymphocytic leukaemia.

SF3B1 is the largest subunit of the Spliceosome Factor 3b (SF3B) complex and part of the U2 small nuclear ribosomal protein. It functions as an important part of spliceosomal assembly, converting precursor messenger RNA (mRNA) to mRNA ready for ribosomal translation. Mutations of are commonly seen in myelodysplastic syndromes with ring sideroblasts (MDS-RS)and MDS/myeloproliferative neoplasm (MPN-RS-T). These mutations are typically heterozygous missense substitutions, of which, 55% involve K700E. MDS-RS a...

Chronic lymphocytic leukaemia: from genetics to treatment.

Chronic lymphocytic leukaemia (CLL), the most frequent type of leukaemia in adults, is a lymphoproliferative disorder that is characterized by the expansion of monoclonal, mature CD5CD23 B cells in the peripheral blood, secondary lymphoid tissues and bone marrow. CLL is an incurable disease with a heterogeneous clinical course, for which the treatment decision still relies on conventional parameters (such as clinical stage and lymphocyte doubling time). During the past 5 years, relevant advances have been ...


Inhibition of bromodomain and extra-terminal proteins increases sensitivity to venetoclax in chronic lymphocytic leukaemia.

The development of drugs able to target BTK, PI3k-delta and BCL2 has dramatically improved chronic lymphocytic leukaemia (CLL) therapies. However, drug resistance to these therapies has already been reported due to non-recurrent changes in oncogenic pathways and genes expression signatures. In this study, we investigated the cooperative role of the BCL2 inhibitor venetoclax and the BRD4 inhibitor JQ1. In particular, we found that JQ1 shows additional activity with venetoclax, in CLL cell lines and in ex viv...

Survival continues to increase in chronic lymphocytic leukaemia: a population-based analysis among 20 468 patients diagnosed in the Netherlands between 1989 and 2016.

Distinct immunoglobulin heavy chain variable region gene repertoire and lower frequency of del(11q) in Taiwanese patients with chronic lymphocytic leukaemia.

Chronic lymphocytic leukaemia (CLL) is the most common leukaemia in Western countries but very rare in Asia. Peripheral blood or bone marrow mononuclear cells obtained at initial diagnosis from 194 patients with CLL were analysed to determine the ethnic difference in genetic abnormalities. Mutated IGHV was detected in 71·2% of Taiwanese CLL and IGHV3-23 was the most frequently used gene. Stereotyped BCR was present in 18·3% with subset 8 being the most frequent. All cases with subset 8 belonged to IGHV 4-...

The Impact and Prognostic Significance of Chronic Lymphocytic Leukemia Upregulated 1 (CLLU1) Gene Expression in Patients with Chronic Lymphocytic Leukemia: A Single Center Experience.

To determine CLLU1 gene levels and the relationship of that gene among other prognostic parameters in patients with chronic lymphocytic leukemia.

Multiple peritricuspidal reentry tachycardias after cardiac infiltration by leukaemia: a case report.

Cardiac involvement by malignant lymphocytic neoplasms is a rare phenomenon. Little is known concerning cardiotoxicity in the chronic phase after completion of treatment.

Chronic myelomonocytic leukaemia: leukaemia cutis predicts disease progression.

Comparison of Transcript Variants Between Patients With Chronic Myeloid Leukaemia and Leukaemia Cell Lines.

Chronic myeloid leukaemia (CML) is a myeloproliferative disorder characterized by the presence of breakpoint cluster region-Abelson murine leukemia (BCR-ABL1) gene fusion as a hallmark that is expressed as two major transcripts b2a2 and b3a2. The aim of this study was to compare the BCR-ABL transcripts in the blood cells of patients with CML, and in chemoresistant and chemosensitive CML cell lines to validate their use as a good method to elucidate CML biology.

Thoracic aortic dissection associated with involvement by small lymphocytic lymphoma/chronic lymphocytic leukemia: a possible underappreciated risk factor?

We report a case of a 77-year-old man with small lymphocytic lymphoma/chronic lymphocytic leukemia (SLL/CLL) thought to be in remission who developed an acute type A thoracic aortic dissection despite no known risk factors for aortic dissection. Surgical pathology evaluation of the aorta specimen removed at surgery showed direct lymphocytic infiltration of the aortic adventitia and media in the region of the aortic dissection. The potential causative role and pathophysiologic mechanisms of SLL/CLL in aortic...

Hypercalcemia in a Patient with Small Lymphocytic Lymphoma/Chronic Lymphocytic Leukemia.

A new risk model to predict time to first treatment in Chronic Lymphocytic Leukemia based on heavy chain immunoparesis and summated free light chain.

Chronic Lymphocytic Leukemia (CLL) is frequently accompanied by immune dysregulation.

Complex karyotype as a predictor of high-risk chronic lymphocytic leukemia: A single center experience over 12 years.

A complex karyotype (CK) is considered a poor prognostic marker in chronic lymphocytic leukemia (CLL).

Large granular lymphocytic laeukemia after solid organ and haematopoietic stem cell transplantation.

T-cell large granular lymphocytic leukaemia (T-LGLL) is a chronic clonal lymphoproliferative disorder of cytotoxic T lymphocytes which commonly occurs in older patients and is often associated with autoimmune diseases. Among 246 patients with T-LGLL seen at our institution over the last 10 years, we encountered 15 cases following solid organ or haematopoietic stem cell transplantation. Here, we studied the clinical characterization of these cases and compared them to de novo T-LGLL. This experience represe...

Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia.

Data regarding the efficacy of treatment with ibrutinib-rituximab, as compared with standard chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab, in patients with previously untreated chronic lymphocytic leukemia (CLL) have been limited.

How to Choose the Best Treatment and Testing for Chronic Lymphocytic Leukemia in the Tsunami of New Treatment Options.

Treatment of chronic lymphocytic leukemia (CLL) has undergone a major shift since introduction of multiple targeted agents. B cell receptor inhibitors that target either bruton tyrosine kinase (ibrutinib) or phosphatidylinositol 3-kinases (idelalisib and duvelisib) and BCL-2 inhibitor venetoclax have become the mainstay of treatment.

Peripheral T-Cell Lymphoma Arising in Patients With Chronic Lymphocytic Leukemia.

To describe three further cases of anaplastic large cell lymphoma (ALCL) occurring in patients with preexisting chronic lymphocytic leukemia (CLL). We also reviewed the literature of previously published cases.

Chronic lymphocytic leukemia patients with HLA-B27 referred for allogeneic hematopoietic stem cell transplantation do not have worse outcomes: Results of a population-based case series analysis in British Columbia, Canada.

Human leukocyte antigen B27 (HLA-B27), associated with spondyloarthritis, was suggested to be protective against chronic lymphocytic leukemia (CLL). It is hypothesized that HLA-B27 patients may have worse outcome in part related to their other comorbidities.

A SCORING SYSTEM TO PREDICT THE RISK OF ATRIAL FIBRILLATION IN CHRONIC LYMPHOCYTIC LEUKEMIA.

Ibrutinib, the first in class of BTK inhibitor, has improved the management of patients with chronic lymphocytic leukemia. Since ibrutinib can cause atrial fibrillation in 6-16% of cases, it is clinically relevant to identify patients at higher risk to develop atrial fibrillation. Comorbidities associated with a higher risk to develop atrial fibrillation were recapitulated in a scoring system. This model proved to be a valid prognostic tool both in a general chronic lymphocytic leukemia population (n=860) a...

Increased Incidental Thyroid Cancer in Patients With Subclinical Chronic Lymphocytic Thyroiditis.

The autoimmune process and increased TSH associated with chronic lymphocytic thyroiditis (CLT) are factors that may promote development of thyroid cancer. When surgically removed, the cellular changes of CLT are commonly seen surrounding thyroid cancers. This study investigates the malignancy rate in CLT patients when compared with non-CLT patients after thyroidectomy.

Sequential and combination treatments with novel agents in chronic lymphocytic leukemia.

Chemoimmunotherapy has been standard of care in patients with chronic lymphocytic leukemia for a long time. Over the last years, novel agents have produced unprecedented outcomes in treatment-naive and relapsed/refractory chronic lymphocytic leukemia. With the advent of these targeted agents, treatment options have extensively diversified and new questions emerge. It is still unclear whether these novel agents should be used as sequential monotherapies until disease progression or if they should preferably ...

Adherence to the 2018 WCRF/AICR cancer prevention guidelines and chronic lymphocytic leukemia in the MCC-Spain study.

Preventable risk factors for chronic lymphocytic leukemia (CLL) remain largely unknown. The aim of this study was to evaluate the association between adherence to nutrition-based guidelines for cancer prevention and CLL, in the MCC-Spain case-control study.

Plasma B-Cell Maturation Antigen Levels are Elevated and Correlate with Disease Activity in Patients with Chronic Lymphocytic Leukemia.

Chronic lymphocytic leukemia (CLL) is a malignancy of late B cells. In another late B-cell malignancy (multiple myeloma), levels of solubilized B-cell maturation antigen (sBCMA) are elevated and predict outcomes.

Mycobacterium chelonae infection mimicking demodex folliculitis.

A 69-year-old man was admitted to hospital with a three month history of a diffuse eruption of painful crusted erythematous papulopustular lesions involving the face and neck. His medical history included chronic lymphocytic leukaemia on monthly intravenous immunoglobulin infusions, type 2 diabetes mellitus and a previous fungal lung abscess for which he was on prophylactic posaconazole. The eruption had not responded to two weeks of amoxicillin-clavulanate started by his general practitioner. By then, he h...


Quick Search